ClinicalTrials.gg
TerminatedNCT02454439NICD-CRTUpdated Nov 12, 2026

Assessment of Cardiac Resynchronization Therapy in Patients With Wide QRS and Non-specific Intraventricular Conduction Delay: a Randomized Trial

An interventional study of CRT implantation in Heart Failure, sponsored by University Hospital, Clermont-Ferrand. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Other

How we know

Why this study was terminated
funding recruitment issues
Updated Nov 12, 2026Now TerminatedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Heart Failure by University Hospital, Clermont-Ferrand — 2 open to participants now, 3 under way, none of them phase 3. Heart Failure · University Hospital, Clermont-Ferrand.

Started
2015
with 1 other
No phase
6 of 12
1 open now
Registered
6th of 12
by date

Among the 12 studies in Heart Failure by University Hospital, Clermont-Ferrand, this one is one of 2 that started in 2015, is one of 6 with no phase, and was the 6th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

2 of the 12 studies in Heart Failure by University Hospital, Clermont-Ferrand are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Heart Failure by University Hospital, Clermont-Ferrand, or all of them as a file.
02

Study summary

The aim of the NICD-CRT study is to assess whether CRT may be clinically beneficial in HF patients with NICD and reduced ejection fraction on 12-month HF status.

In effect, the effectiveness of cardiac resynchronization therapy in heart failure (HF) with reduced ejection fraction patients with non specific intraventricular conduction delay (NICD) has never been confirmed even if it is recommended.

At the moment, no dedicated study has already been performed to assess the benefit of CRT in patients with NICD. Results from CRT therapy are contradictory in this patient group and have only been obtained from subgroup analysis. Some of them don't show clinical benefit but others show a benefit in term of an end-diastolic and/or end-systolic left ventricular volume (decrease of the size and the volumes of left ventricule).

The AHA/ACCF guidelines, published in 2005 and updated in 2009, considered only QRS duration (≥120 ms) for the indication of CRT implantation, without any consideration for the type of conduction disorder (i.e. LBBB vs. non-LBBB), current updated 2012 ACCF/AHA/HRS guidelines, consider QRS morphology (i.e. LBBB) as the first step for CRT candidate selection in addition to QRS duration (>150 ms). Indications for resynchronization have been restricted since indication of CRT in non-LBBB patients (e.g. NICD) is only a class IIa (>150 ms, only in NYHA III and ambulatory IV; level of evidence A). The same modifications have been applied between 2011 and 2013 in the European guidelines. None is known about patients with NICD and QRS > 130 ms.

Read the detailed description

This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.

  • Patients will be included in thirteen sites in France(Clermont-Ferrand University Hospital, Côte Basque Hospital, Bordeaux University Hospital, Saint-Augustin Clinic, Limoges University Hospital, Grenoble University Hospital, Nantes University Hospital, Nantes New Clinic, Rennes University Hospital, Saint-Etienne University Hospital, Tours University Hospital, Toulouse University Hospital, Georges Pompidou European Hospital) and two sites in the Netherlands (Maastricht University Hospital and Radboud University Medical Center)
  1. At baseline a preimplantation evaluation is performed: clinical examination, ECG, six minute walk test, biology analysis, quality of life assessment, echocardiography, peak oxygen consumption.
  2. At 6 months, evaluation of efficacy which is the secondary assessment criteria:

    • Quality of life: Minnesota Living With Heart Failure Questionnary: MLWHFQ) : improvement of at least 20 points
    • Functionnal capacity :

      • NYHA classification reduction ≥ 1 class,
      • 6-minute walk test improvement of at least 10 % in distance,
      • Peak oxygen consumption increased by 1.0 ml/kg/minNYHA response to CRT is the primary endpoint. It is a composite primary endpoint, including modification of: Quality of Life Score (MINNESOTA scale), NYHA functional status , 6-minute walk test and volume of the left ventricle.
    • Percentage of hospitalizations for HF, for cardiovascular reasons and for all causes Decrease >15% in end-diastolic and/or end-systolic volumes of the left ventricle.
  3. At 12 months, comparison of the proportion of improved, unchanged and worsend patients (Packer Score) in both group which is the primary endpoint and new evaluation of the CRT efficacy (same as 6 months)and comparison of the death and percentage of hospitalization in both group which is the primary endpoint.
03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart Failure with reduced ejection fraction (<35%)
  • Cardiac Resynchronisation Therapy
  • Non specific intraventricular conduction
  • Efficacy
  • Life expectancy expected to exceed one year with a good functional status
  • QRS morphology : NICD according to the AHA/ACCF/HRS Recommendations (non-LBBB and non-RBBB):
  • QRS duration > 130 ms
04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria :

  • Patients over 18 years' old
  • class II to IV ambulatory
  • QRS duration > 130 ms
  • Patients with sinus rhythm
  • \< 35%
  • QRS morphology: NICD according to the AHA/ACCF/HRS9 Recommendations (non-LBBB and non-RBBB):

    • Not broad notched or slurred R wave in leads I, aVL, V5 and V6;
    • Presence of a Q wave in leads I, V5, V6;
    • No rsr', rsR' or rSR' pattern in leads V1 or V2.
  • expected to exceed one year with a good functional status
  • Optimal pharmacological therapy of heart failure according to clinician

Non inclusion criteria :

  • Inability to understand nor decline the study,
  • Impaired mobility,
  • Unable to fill out questionnaire independently,
  • Patients with permanent atrial fibrillation,
  • Pregnant women,
  • Dependant adult,
  • Patients minor,
  • Life expectancy \< 1 year due to other causes than HF.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    CRT-D or CRT-P ON

    This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.

    Other: CRT implantation

  • Other
    CRT-D or CRT-P OFF

    This is a pilot, prospective, controlled, two-parallel arm, randomized, double-blind design and multicentric clinical trial comparing a CRT-D or CRT-P ON group vs. CRT-D or CRT-P OFF group in HF with reduced ejection fraction patients with NICD.

    Other: CRT implantation

Interventions

  • OtherCRT implantation
06

What researchers measure

Primary outcomes

  1. Composite of 2 clinical endpoints combined (12 months all-cause deaths and percentage of hospitalizations for HF at 12 months) combined using an average z-score.

    According to z-score

    Time frame: at 12 months

Secondary outcomes

  1. Evaluation of efficacy, analysis of 12- month deaths

    HF, cardiovascular and all causes deaths

    Time frame: at 6 and 12 months

  2. Evaluation of efficacy, analysis of - Quality-of-life questionnaires

    Minnesota Living With Heart Failure Questionnaire: MLWHFQ): improvement of at least 20 points

    Time frame: at 6 and 12 months

  3. Evaluation of efficacy, analysis of Functional capacity

    NYHA classification reduction ≥ 1 class, 6-minute walk test improvement of at least 10 % in distance, Peak oxygen consumption increased by 1.0 ml/kg/min

    Time frame: at 6 and 12 months

  4. Evaluation of efficacy, analysis of Percentage of hospitalizations for HF

    Time frame: at 6 and 12 months

  5. Evaluation of efficacy, analysis of left ventricule volume by echocardiography transthoracic

    Decrease \>15% in end-diastolic and/or end-systolic volumes of the left ventricle

    Time frame: at 6 and 12 months

  6. Evaluation of efficacy, Packer score

    The proportion of improved, unchanged and worsened patients in both groups. Patients are considered improved if at the final visit they experienced a favorable change in NYHA functional class or in the patient global assessment (or both) of a prespecified magnitude but did not experience any major adverse clinical events during the course of the trial. Patients are considered worse if they experienced a major clinical event during the planned duration of double-blind treatment or reported worsening of their NYHA class or global assessment at the final visit. Patients are considered unchanged if they are neither improved nor worse.

    Time frame: at 6 and 12 months

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63003, France
08

References and documents

Publications

  • Eschalier R, Ploux S, Pereira B, Clementy N, Da Costa A, Defaye P, Garrigue S, Gourraud JB, Gras D, Guy-Moyat B, Leclercq C, Mondoly P, Bordachar P. Assessment of cardiac resynchronisation therapy in patients with wide QRS and non-specific intraventricular conduction delay: rationale and design of the multicentre randomised NICD-CRT study. BMJ Open. 2016 Nov 11;6(11):e012383. doi: 10.1136/bmjopen-2016-012383. PubMed 27836874 ↗
09

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Jul 2015, a primary completion of May 2026 and a completion of May 2026. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jul 2023 → May 2026 and completion Jul 2024 → May 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2015
First posted
May 27, 2015
Start
Jul 2015
Primary completionActual
May 26, 2026was Jul 2023
CompletionActual
May 26, 2026was Jul 2024
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Terminated funding recruitment issues
changed Nov 12, 2026
Primary completion
Jul 2023→May 26, 2026 (actual)
Nov 12, 2026
Study completion
Jul 2024→May 26, 2026 (actual)
Nov 12, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedQRS morphology: NICD according to the AHA/ACCF/HRSHRS9 Recommendations (non-LBBB and non-RBBB):
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Status unknown→Terminated
    Why stopped funding recruitment issues
    Primary completion Jul 2023→May 26, 2026 (now actual)
    Study completion Jul 2024→May 26, 2026 (now actual)
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedQRS morphology: NICD according to the AHA/ACCF/HRSHRS9 Recommendations (non-LBBB and non-RBBB):
    + 2 other changes: contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02454439
Responsible party
Sponsor
First posted
May 27, 2015
Start date
Jul 2015
Primary completion
May 26, 2026
Completion
May 26, 2026
Last update
Nov 12, 2026

Study contacts

Romain ESCHALIER
principal investigator · University Hospital, Clermont-Ferrand
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion